Department of Gastroenterology and Hepatology, Erasmus MC Transplant Institute, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands.
Department of Surgery, Division of Hepatopancreaticobiliary and Transplant Surgery, Erasmus MC Transplant Institute, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands.
Transpl Int. 2021 Aug;34(8):1455-1467. doi: 10.1111/tri.13925. Epub 2021 Jun 28.
Liver transplantation for primary sclerosing cholangitis (PSC) can be complicated by recurrence of PSC (rPSC). This may compromise graft survival but the effect on patient survival is less clear. We investigated the effect of post-transplant rPSC on graft and patient survival in a large European cohort. Registry data from the European Liver Transplant Registry regarding all first transplants for PSC between 1980 and 2015 were supplemented with detailed data on rPSC from 48 out of 138 contributing transplant centres, involving 1,549 patients. Bayesian proportional hazards models were used to investigate the impact of rPSC and other covariates on patient and graft survival. Recurrence of PSC was diagnosed in 259 patients (16.7%) after a median follow-up of 5.0 years (quantile 2.5%-97.5%: 0.4-18.5), with a significant negative impact on both graft (HR 6.7; 95% CI 4.9-9.1) and patient survival (HR 2.3; 95% CI 1.5-3.3). Patients with rPSC underwent significantly more re-transplants than those without rPSC (OR 3.6, 95% CI 2.7-4.8). PSC recurrence has a negative impact on both graft and patient survival, independent of transplant-related covariates. Recurrence of PSC leads to higher number of re-transplantations and a 33% decrease in 10-year graft survival.
原发性硬化性胆管炎(PSC)患者行肝移植后可能会出现 PSC 复发(rPSC)。这可能会影响移植物的存活率,但对患者生存率的影响尚不清楚。我们在一个大型欧洲队列中研究了移植后 rPSC 对移植物和患者生存率的影响。欧洲肝移植登记处的登记数据涵盖了 1980 年至 2015 年间所有的 PSC 首次移植,其中 138 个参与移植中心中的 48 个中心提供了详细的 rPSC 数据,涉及 1549 名患者。采用贝叶斯比例风险模型研究了 rPSC 及其他协变量对患者和移植物存活率的影响。在中位随访 5.0 年后(2.5%-97.5%分位数:0.4-18.5),259 例(16.7%)患者诊断出 rPSC,rPSC 对移植物(HR 6.7;95% CI 4.9-9.1)和患者生存率(HR 2.3;95% CI 1.5-3.3)均有显著负面影响。rPSC 患者与无 rPSC 患者相比,再次移植的比例明显更高(OR 3.6,95% CI 2.7-4.8)。rPSC 复发对移植物和患者生存率均有负面影响,独立于移植相关的协变量。rPSC 的复发导致更多的再次移植,并使 10 年移植物存活率降低 33%。